Cannabidiol (CBD) is a non-intoxicating compound found in Cannabis sativa, increasingly studied for its potential therapeutic applications in conditions such as epilepsy, anxiety and chronic inflammation. Its regulatory treatment varies widely across jurisdictions — from approved pharmaceutical preparations to ambiguous food, cosmetic and supplement categories — generating ongoing tension between scientific evidence, market expansion and public policy. ICEERS examines CBD from clinical, regulatory and human rights perspectives. This tag gathers content on CBD’s effects, evidence base, safety considerations, product quality issues, and regulatory debates.
